Juan Miguel Pech León (@juanmiguelpechl) 's Twitter Profile
Juan Miguel Pech León

@juanmiguelpechl

All you need is Radiation

ID: 40301612

calendar_today15-05-2009 18:34:09

4,4K Tweet

322 Followers

868 Following

Gustavo (@gusviani) 's Twitter Profile Photo

🎙️ eliminating ENI is oncologically sound for #HNSCC and more prospective studies are needed ❗️OncoAlert 📌Ph2 study eliminating ENI & treating involved/ suspicious LN w/ IMRT 🥇🎯: solitary elective volume recurrence 📊RESULTs 👉67 👥 HNSCC➡️18 larynx/hypopharynx & 49

🎙️ eliminating ENI is oncologically sound for #HNSCC and more prospective studies are needed ❗️<a href="/OncoAlert/">OncoAlert</a> 
📌Ph2 study eliminating ENI &amp; treating involved/ suspicious LN w/ IMRT
🥇🎯: solitary  elective volume recurrence
📊RESULTs 
👉67 👥 HNSCC➡️18 larynx/hypopharynx &amp; 49
Gustavo (@gusviani) 's Twitter Profile Photo

🎙️Hypo RT shows comparable long term results to the standard of care for #GBM❗️❗️OncoAlert Journal of Neuro-Oncology 📌Ph2 89 GBM 👥 post-🔪 ➡️ randomized to CRT or HART -CRT= 60 Gy /30 fr; HART= 60 Gy /20 +TMZ both arms 🥇🎯: 5y OS &PFS 📊RESULTs 👉Median OS 26.5 m HART✖️22.4 m CRT 👉N🚫

🎙️Hypo RT shows comparable long term results to the standard of care for #GBM❗️❗️<a href="/OncoAlert/">OncoAlert</a>  <a href="/JNeurooncol/">Journal of Neuro-Oncology</a> 
📌Ph2 89 GBM 👥 post-🔪 ➡️ randomized to CRT or HART
-CRT= 60 Gy /30 fr; HART= 60 Gy /20 +TMZ both arms
🥇🎯: 5y OS &amp;PFS
📊RESULTs
👉Median OS 26.5 m HART✖️22.4 m CRT
👉N🚫
Yüksel Ürün (@dryukselurun) 's Twitter Profile Photo

New study on muscle invasive bladder cancer treatments 🩺: Bladder preserving therapy (BPT) shows comparable 2-year disease-free survival to radical cystectomy (RC). Both methods could be curative options! 🌟 #bladdercancer OncoAlert

New study on muscle invasive bladder cancer treatments 🩺:
 Bladder  preserving therapy (BPT) shows comparable 2-year disease-free survival  to radical cystectomy (RC). Both methods could be curative options! 🌟  #bladdercancer <a href="/OncoAlert/">OncoAlert</a>
eContour (@econtourradonc) 's Twitter Profile Photo

If you love contouring (or even if you don't 😁), get your pencil & brush ready!! 🖊✏ 🖌 Our annual travel grant w ACRO - American College of Radiation Oncology ACROresident & MIM Software is back! Don't see a case you want on our website? Submit your proposal here 👇🏽 acro.org/page/annual-me…

If you love contouring (or even if you don't 😁), get your pencil &amp; brush ready!! 🖊✏ 🖌

Our annual travel grant w <a href="/ACRORadOnc/">ACRO - American College of Radiation Oncology</a> <a href="/ACROresident/">ACROresident</a> &amp; <a href="/mimsoftware/">MIM Software</a> is back!

Don't see a case you want on our website? Submit your proposal here 👇🏽

acro.org/page/annual-me…
Elliot K Fishman / CTisus.com (@ctisus) 's Twitter Profile Photo

Happy 52nd birthday to the CT scan! On this day in 1971, the first CT scan was performed in London on a novel device invented by Sir Godfrey Hounsfield and Dr. Allan Cormack. The rest is history.

Happy 52nd birthday to the CT scan!

On this day in 1971, the first CT scan was performed in London on a novel device invented by Sir Godfrey Hounsfield and Dr. Allan Cormack.  The rest is history.
Olga Kobzar the Best ( Кобзар Ольга ) (@olgakobzarbest) 's Twitter Profile Photo

Никто не может лгать, никто не может всё скрыть, когда он смотрит прямо в чьи-то глаза...

Никто не может лгать, никто не может всё скрыть, когда он смотрит прямо в чьи-то глаза...
Orlando RPN (@orlandorpn) 's Twitter Profile Photo

Estimados amigos Imagenólogos y técnicos radiólogos, la Lesión Renal Aguda por Contraste NO EXISTE desde hace décadas, favor de No negar los estudios contrastados ni pedir Cr sérico obligatoria o firma de algún incauto responsable. Al contrario, se asocia a menor mortalidad de

Estimados amigos Imagenólogos y técnicos radiólogos, la Lesión Renal Aguda por Contraste NO EXISTE desde hace décadas, favor de No negar los estudios contrastados ni pedir Cr sérico obligatoria o firma de algún incauto responsable. Al contrario, se asocia a menor mortalidad de
David A. Forero-Peña MD. (@davidforeromd) 's Twitter Profile Photo

¡Dejen de llamarlo #Dengue hemorrágico por favor! Hace 14 años que hay una nueva clasificación. Aquí les cuento todo lo que usted tiene que saber sobre #Dengue. 🧵

¡Dejen de llamarlo #Dengue hemorrágico por favor! 

Hace 14 años que hay una nueva clasificación. Aquí les cuento todo lo que usted tiene que saber sobre #Dengue.

🧵
Jeff Ryckman (@jryckman3) 's Twitter Profile Photo

EMBRACE II: New standard of care for locally advanced cervical cancer! 📌 Advanced RT technology. 📌 Image-guided adaptive brachytherapy. 📌 Limited overall treatment time. 📌 Excellent disease control and overall survival. 📌 Low late severe morbidity. #ESTRO2025

EMBRACE II: New standard of care for locally advanced cervical cancer!

📌 Advanced RT technology.
📌 Image-guided adaptive brachytherapy.
📌 Limited overall treatment time.
📌 Excellent disease control and overall survival.
📌 Low late severe morbidity.

#ESTRO2025
Todd Scarbrough (@toddscarbrough) 's Twitter Profile Photo

1/ #ESTRO2025 FAST FORWARD 10 year breast cancer results are out 40 Gy/15 fx vs 27/5 fx vs 26/5 Most women were >50y and T1N0 low risk The recurrence rate at 10y for the 26 Gy arm: 2.0% This is an INSANELY low number for risk of (any) cancer coming back To put in context:

1/
#ESTRO2025

FAST FORWARD 10 year breast cancer results are out

40 Gy/15 fx vs 27/5 fx vs 26/5

Most women were &gt;50y and T1N0 low risk

The recurrence rate at 10y for the 26 Gy arm:
2.0%

This is an INSANELY low number for risk of (any) cancer coming back

To put in context:
Dr. Nina Niu Sanford (@niusanford) 's Twitter Profile Photo

Comparison of toxicity w 3D v IMRT in RAPIDO: IMRT worse. Table summarizes studies of 3D v IMRT in rectal ca – w RAPIDO, data mixed. Caveat that RAPIDO didn’t require OAR delineation/ specify constraints, but good reminder that advanced tech doesn’t guarantee better outcomes.

Comparison of toxicity w 3D v IMRT in RAPIDO: IMRT worse.

Table summarizes studies of 3D v IMRT in rectal ca – w RAPIDO, data mixed.

Caveat that RAPIDO didn’t require OAR delineation/ specify constraints, but good reminder that advanced tech doesn’t guarantee better outcomes.